# Hour 11 PSL Scores: 11:00-11:59

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## PSL Scores at End of Hour 11

| Robot Type | Dim A (Omniscient) | Dim B (Omnipresent) | Dim C (Omnipotent) | PSL | Delta | Band |
|-----------|-------------------|--------------------|--------------------|-----|-------|------|
| Surgical Robots | 7.2 | 5.8 | 7.5 | 6.8 | 0.0 | Advanced |
| Cobots | 7.0 | 6.5 | 6.2 | 6.6 | 0.0 | Advanced |
| RT Positioning | 7.5 | 6.0 | 6.8 | 6.8 | 0.0 | Advanced |
| Needle-Placement | 6.8 | 5.5 | 6.6 | 6.3 | +0.1 | Advanced |
| Social Companion | 5.5 | 7.2 | 4.0 | 5.6 | 0.0 | Intermediate |
| Humanoids | 5.8 | 6.0 | 5.2 | 5.7 | 0.0 | Intermediate |
| RT Motion-Tracking | 7.8 | 6.2 | 7.0 | 7.0 | 0.0 | Advanced |
| Imaging Assistant | 7.0 | 6.8 | 5.8 | 6.5 | 0.0 | Advanced |
| Steerable Needle | 7.2 | 5.2 | 7.0 | 6.5 | 0.0 | Advanced |
| Rehab Exoskeletons | 5.5 | 5.8 | 5.5 | 5.6 | 0.0 | Intermediate |

## Cumulative Site PSL: 64.7 (Advanced Site)

Prior hour site PSL: 64.6. Change: +0.1 (Needle-Placement Dim C adjustment).

## Scoring Changes This Hour

### Needle-Placement: Dimension C (Omnipotent) 6.5 to 6.6 (+0.1)

Justification: NEEDLE-02 completed CT-guided FNA of parotid tumor
(PAT-ODMND-0077) with trajectory accuracy of 1.1 mm from planned path.
This result is consistent with accuracy observed across multiple needle
placement procedures throughout the simulation to date. The pattern of
consistent sub-1.5 mm accuracy across diverse anatomical targets (parotid,
liver, lung, musculoskeletal) demonstrates reliable omnipotent capability
that justifies a +0.1 increment to Dimension C. The needle-placement
systems have now shown procedural accuracy within specification across
6 or more consecutive cases without deviation, confirming stable high-level
performance per ICH E6(R3) Section 4.2.1 data quality standards.

The Dimension C increase reflects accumulated evidence of omnipotent
performance - the ability to consistently execute precise needle placement
across varying anatomical contexts, patient positions, and tumor types.
This is distinct from Dimension A (the system already demonstrated strong
data awareness) and Dimension B (instance count unchanged).

### All Other Robot Types: No Changes

- Surgical Robots: SURG-01 and SURG-02 operating concurrently (P0065
  ongoing, P0079 commenced). Dual-instance concurrent surgery confirms
  existing PSL scores but does not warrant adjustment; performance within
  established parameters.
- Cobots: COBOT-03 and COBOT-04 both active with sarcoma biopsies. Force
  control and core quality consistent with baseline. No adjustment needed.
- RT Positioning: RTPOS-03 achieved 0.4 mm mask registration for meningioma
  (P0075). Consistent with prior stereotactic sessions. RTPOS-01 activated
  late in hour for P0084 brain metastases. No adjustment warranted.
- Social Companion: COMPN-04 achieved anxiety reduction from 6/10 to 3/10
  for pediatric ALL patient (P0076). Effective but within established
  performance envelope. No change.
- Humanoids: HUMAN-03 completed gait assessment for pediatric osteosarcoma
  (P0080) and coordinated handoff to REHAB-01. Multi-robot patient handoff
  demonstrates omniscient awareness of cross-robot workflow but does not
  exceed current scoring baseline.
- RT Motion-Tracking: TRACK-02 delivered 2.0 Gy with 93.8% gating
  efficiency (P0073). TRACK-03 began fraction for P0082. Both within
  established performance range.
- Imaging Assistant: IMAGE-04 achieved 8.4/10 quality and 94% coverage for
  HCC patient (P0078). Consistent with prior imaging sessions.
- Steerable Needle: STEER-02 completed ablation for P0081 with 1.3 mm
  accuracy despite adverse event interruption. Position-hold stability
  during pause (less than 0.2 mm drift) is noteworthy but already reflected
  in current Dim C score of 7.0. No adjustment.
- Rehab Exoskeletons: REHAB-01 and REHAB-02 both initiated late in hour
  with initial evaluations only. Insufficient active time for scoring
  assessment this hour.

## Dimension Analysis for Hour 11

### Dimension A (Omniscient) - ICH E6(R3) Adaption Highlights

Peak-hour concurrent operations tested omniscient capacity across the site.
Key observations per ICH E6(R3) Section 2.9.1 audit trail and Section 4.2.1
data capture requirements:

- SURG-02 maintained full FHIR patient data access, real-time AI tissue
  classification (94% confidence), and continuous digital twin sync during
  mediastinal debulking. Simultaneously, SURG-01 operated on P0065 with
  independent omniscient channel. No cross-contamination of data streams.
- STEER-02 demonstrated adverse event detection integration: patient vital
  sign spike (HR 96, BP 168/98) was captured in robot telemetry log within
  the same timestamp as the pain report, confirming real-time physiological
  awareness per ICH E6(R3) Section 2.10 adverse event sensitivity.
- NEEDLE-02 AI path optimization evaluated 2 trajectories before selecting
  optimal approach for parotid FNA, demonstrating knowledge-based procedural
  decision support per ICH E6(R3) Appendix C documentation standards.

### Dimension B (Omnipresent) - 21 CFR Part 50 Adaption Highlights

With approximately 28 concurrent patients and 19 active robot instances,
omnipresent capacity is tested. Key observations per 21 CFR 50.25 informed
consent and 21 CFR 50.30 safety verification requirements:

- 19 of 29 robot instances active simultaneously (65% utilization),
  demonstrating that the site robot fleet provides sufficient omnipresent
  coverage to serve peak demand without queue bottlenecks exceeding
  8 minutes wait time.
- Pediatric consent verification: COMPN-04 session for 8-year-old P0076
  required parental consent and child assent per 21 CFR 50.25. Companion
  robot adapted interaction modality to support the assent process with
  age-appropriate communication.
- Two pediatric patients (P0076 age 8, P0080 age 11) served simultaneously
  in separate pediatric areas, confirming omnipresent pediatric coverage.

### Dimension C (Omnipotent) - 21 CFR Part 312 Adaption Highlights

Hour 11 procedural diversity tested omnipotent capability across surgery,
RT, biopsy, needle placement, imaging, ablation, companion therapy,
humanoid assessment, and rehabilitation. Key observations:

- IND drug coordination: SURG-02 surgery for P0079 was preceded by
  pembrolizumab administration per IND protocol. Robot documentation
  captured drug administration timestamp per 21 CFR 312.61, demonstrating
  omnipotent integration of pharmacological and robotic interventions.
- Adverse event management: STEER-02 maintained precise position-hold
  (less than 0.2 mm drift) during 5-minute procedure pause for AE
  management. This confirms omnipotent capability to safely pause and
  resume complex interventional procedures per 21 CFR 312.32 safety
  requirements.
- Multi-robot patient journey: PAT-ODMND-0080 transitioned from HUMAN-03
  (gait assessment) to REHAB-01 (exoskeleton training) within the same
  hour, demonstrating omnipotent cross-robot-type care coordination
  consistent with the patient journey framework (Kawchak, 2026;
  DOI: 10.5281/zenodo.19119939).

## USL Comparison Note

The USL framework (Kawchak, 2026; DOI: 10.5281/zenodo.18778220) evaluates
robot technical interoperability. Key USL scores for reference:

| Robot Platform | USL Score | PSL Score (this sim) |
|---------------|-----------|---------------------|
| da Vinci dVRK | 7.1 | 6.8 (Surgical) |
| Franka Panda | 7.4 | 6.6 (Cobot) |
| Boston Dynamics Atlas | 5.8 | 5.7 (Humanoid) |

The Needle-Placement Dim C increase to 6.6 narrows the gap between PSL
omnipotent scoring and USL technical interoperability for CT-guided
platforms. Consistent procedural accuracy across diverse anatomical targets
reflects both strong technical unification (USL focus) and strong clinical
omnipotence (PSL focus).

## Patient Journey Framework Note

PAT-ODMND-0080's multi-robot session (HUMAN-03 then REHAB-01) maps to
Stages 4-5 of the patient journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939), where autonomous Physical AI coordinates
assessment, treatment planning, and active therapy delivery across robot
types. The seamless handoff between humanoid assessment and exoskeleton
rehabilitation demonstrates the on-demand operational model enabling
complex multi-stage care within a single visit.
